

# Mechanism of Action of Bone Marrow Concentrates

Rowan Paul, M.D.



ROWAN PAUL, MD  
**RegenCore**  
SAN FRANCISCO, CA  
ASIPP 2022  
LAS VEGAS, NV

# Disclosures

RELEVANT FINANCIAL RELATIONSHIPS IN THE PAST TWELVE MONTHS BY PRESENTER OR SPOUSE/PARTNER.

**SPEAKERS BUREAU:** The Orthobiologic Institute (TOBI), Boston Biolife, Global Regenerative Academy

**STOCK SHAREHOLDER:** N/A

**GRANT/RESEARCH SUPPORT:** N/A

**CONSULTANT:** Benchmark Biomedical, MiniTC


**MEDICAL ADVISORY BOARDS:** Altis.AI,, DataBiologics, MONJ, ROAM Robotics

**THE SPEAKER WILL DIRECTLY DISCLOSE THE USE OF PRODUCTS FOR WHICH ARE NOT LABELED (E.G., OFF LABEL USE) OR IF THE PRODUCT IS STILL INVESTIGATIONAL.**

# Objectives

- ▶ Understand the principles of the use of Bone Marrow Concentrate (BMC) in regenerative musculoskeletal care
- ▶ Understand what a Mesenchymal Stromal/Stem Cell is
- ▶ Understand the differences between BMC and PRP
- ▶ Learn some of the evidence that supports BMC
- ▶ Understand the importance of draw technique, equipment and image guidance.

# Bone Marrow Concentrates



## Density separation in g/mL.

Plasma: 1.025 – 1.029

Platelets: 1.060 – 1.067

Monocytes: 1.062 – 1.068


Lymphocytes: 1.068 – 1.072

HSCs: 1.069 – 1.071

MSCs: 1.073 – 1.077

Neutrophils: 1.080 – 1.090

Erythrocytes: 1.086 – 1.100



# The Promise



Orthobiologics like BMAC are safe, minimally invasive and may provide a definitive solution for patients in the treatment gap.




Reducing the need and use of corticosteroids, NSAIDs and Opioids



Reducing unnecessary, overly invasive surgery

# The Reality



We start off confused and end up confused on a higher level.

Alan Chalmers

aptorancy

# Bone Marrow Concentrate Landscape

- ▶ Orthopedic surgeons have used Bone Marrow Aspirate for decades
- ▶ Hernigou et al, has been injecting BMAC into AVN of the hip and knees as a successful alternative to joint replacement for decades
- ▶ Mesenchymal Stem/Stromal Cells (MSC's) are multi-potent and can differentiate into bone, cartilage, fat, etc.
- ▶ MSC's, HSC's are found in Bone Marrow Aspirates
- ▶ Cortisone has been shown to have adverse side-effects with repeated exposure
- ▶ Regulatory controversies



# Is it Safe?

## A multi-center analysis of adverse events among two thousand, three hundred and seventy two adult patients undergoing adult autologous stem cell therapy for orthopaedic conditions

Christopher J Centeno <sup>1</sup>, Hasan Al-Sayegh <sup>2</sup>, Michael D Freeman <sup>3 4</sup>, Jay Smith <sup>5</sup>, William D Murrell <sup>6</sup>, Rostyslav Bubnov <sup>7</sup>

- ▶ 3012 MSC based procedures
- ▶ 325 Adverse events
  - ▶ Pain (3.9%), and pain due to progressive joint disease (3.8%)
- ▶ 2.2 years Bone Marrow and/or Adipose
- ▶ 3.9% pain from procedure
- ▶ 3.8% pain from DJD
- ▶ 7 neoplasms total= LOWER incidence than the general population with BMC being the lowest incidence
- ▶ Bone Marrow Concentrate (BMC) safer than Adipose or BMC+Adipose or cultured cells (illegal in the US)

## Cancer risk is not increased in patients treated for orthopaedic diseases with autologous bone marrow cell concentrate


Philippe Hernigou<sup>1</sup>, Yasuhiro Homma<sup>2</sup>, Charles-Henri Flouzat-Lachaniette<sup>1</sup>, Alexandre Poignard<sup>1</sup>,  
Nathalie Chevallier<sup>1</sup>, Helene Rouard<sup>1</sup>

- ▶ 12.5 year follow-up data
- ▶ 1837 patient s/p BMAC
- ▶ No increased cancer/tumor risk at the site of placement or other distant site



Are there data for Bone Marrow  
Concentrates?

## MSC PUBLICATIONS PER YEAR IN PUBMED



Rowan Paul, M.D.

# MSC Publications- The hype AND the data are building

<https://regenexx.com/blog/mesenchymal-stem-cell-research-continues-to-increase/>


# 2021 Bone Marrow Stem Cell Infographic

Some physicians and scientists argue that we don't have much research supporting the use of bone marrow stem cells to treat orthopedic conditions. Here I list all significant publications from the late 90s through April 2021. The list was compiled by running various searches on body parts and bone marrow cell types on PubMed. Each circle represents a research study and is hyperlinked to the abstract in the U.S. National Library of Medicine or the full text article. The main author is listed, the area of treatment, the number of patients involved or treated with bone marrow cells, and the type of bone marrow stem cells used (either Autologous Bone Marrow Concentrate (BMC), Bone Marrow Aspirate (BMA) or Cultured Mesenchymal Stem Cells (MSC Cult) [autologous or allogeneic]. The scalpel or injection icons represent the three types of delivery techniques: injection, surgical, or both. Regenxx publications are highlighted in yellow. Case series smaller than 5 patients, unless publishing on original concepts were excluded.



If you're interested in using this slide in presentations, please request permission in writing from Chris Centeno, M.D. at [centenoffice@centenoschultz.com](mailto:centenoffice@centenoschultz.com).

2010



2015



2018



2019



2020



2021



Rowan Paul, M.D.

Rowan Paul, M.D.

# What is in Bone Marrow?

- ▶ Cellular and non-cellular components
- ▶ Marrow stroma- heterogenous population of cells
  - ▶ Fibroblasts, adipocytes, osteoblasts, osteoclasts, macrophages, endothelial cells
  - ▶ MSCs and HSCs
  - ▶ Platelets and erythrocytes
  - ▶ Mononuclear cells
    - ▶ Endothelial progenitors

# ISCT Classification for MSCs

**Table 1:** Negative and Positive MSC Markers as Proposed by the International Society for Cell Therapy (ISCT)

| Negative HSC Marker                     | Used to Exclude                                                                                                    | Peer-reviewed References |
|-----------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------|
| CD34 <sup>20,21</sup>                   | Primitive hematopoietic cells and endothelial cells <sup>22</sup>                                                  | 23, 24                   |
| CD45 <sup>20,21</sup>                   | Leukocytes <sup>25</sup>                                                                                           | 26, 27                   |
| CD11b and CD14 <sup>20,21</sup>         | Monocytes and macrophages <sup>28,29</sup>                                                                         | 27, 30                   |
| CD79 alpha and CD19 alpha <sup>31</sup> | B cells <sup>32</sup>                                                                                              | 33, 34                   |
| HLA Class II31                          | Antigen presenting cells and lymphocytes <sup>1,35*</sup>                                                          | 36, 37                   |
| Positive MSC Markers                    | Biological Role                                                                                                    | Peer-reviewed References |
| CD73/5'-Nucleotidase <sup>21</sup>      | Catalyzes production of extracellular adenosine from AMP <sup>38</sup>                                             | 39, 40                   |
| CD90/Thy1 <sup>20</sup>                 | Wound repair, cell-cell and cell-matrix interactions <sup>41</sup> ; see Figure 2                                  | 27, 42                   |
| CD105/Endoglin <sup>21</sup>            | Vascular homeostasis; modulates TGF-beta functions via interaction with TGF-beta RI and TGF-beta RII <sup>43</sup> | 24, 36, 44               |

\*HLA Class II may be expressed on stimulated MSCs.




**Figure 2. Detection of CD90/Thy1 in Human Mesenchymal Stem Cells by Flow Cytometry.** Human mesenchymal stem cells were stained with Sheep Anti-Human/Porcine/Canine CD90/Thy1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF2067, filled histogram) or isotype control antibody (Catalog # 5-001-A, open histogram),

# ISCT MSC recommendation


- ▶ Cells must adhere to plastic in culture conditions
- ▶ Must express CD markers 73,90,105
- ▶ Cannot express CD34, 45, 14, 11b, 19
- ▶ Cannot express HLA-DR
- ▶ Should be able to differentiate into osteoblasts, chondroblasts, adipocytes in vitro

# Immunomodulation by Therapeutic Mesenchymal Stromal Cells is Triggered Through Phagocytosis of MSC by Monocytic Cells

Samantha F.H. De White et al 2018 Stem Cells

- ▶ “Primed Monocytes”
  - ▶ ↓Decreasing M1 markers , ↑ M2 markers
  - ▶ Via MSC debris uptake in the blood stream
  - ▶ Decreased
    - ▶ Classical (Non-primed monocytes)
    - ▶ TNF-A
  - ▶ Increased
    - ▶ Intermediate Monocytes
    - ▶ PD-L1, CD90 expression
    - ▶ IL-6, IL-8, IL-1B expression
    - ▶ TGF-B and IL-10


# Traditional thinking on mechanism




<https://www.rndsystems.com/pathways/mesenchymal-stem-cell-differentiation-pathways-lineage-specific-markers>

# Updated thinking on mechanism

MSCs respond to inflammation, cell damage/death, cell malnutrition, and infection with various factor secretions/exosomes



# Paracrine Effect



<https://www.intechopen.com/source/html/50942/media/fig2.png>

# BMC is NOT PRP with a few Stem Cells

Cassano KSSTA 2016

- ▶ N=29, mean age 48 years, (23-68)
- ▶ Bone Marrow
  - ▶ CFU, Multi-lineage Differentiation
  - ▶ Flow Cytometry:
    - ▶ CD271, CD73, CD146, CD34, CD45
- ▶ Whole Blood, PRP, BMC in common have
  - ▶ Cytology:
    - ▶ Leukocytes (Lymphocytes, Neutrophils, Monocytes, Eosinophils, Basophils)
    - ▶ Platelets

Cytokines:

Anabolic: PDGF TGF-  $\beta$  1,2,3, FGF, IL-1 $\alpha$

Catabolic: IL-1 $\beta$ , IL-6, IL-8, TNF- $\alpha$ , IFN $\gamma$

# BMC is NOT PRP with a few Stem Cells

Cassano KSSTA 2016

|             | PRP            | BMC            | P value |
|-------------|----------------|----------------|---------|
| WBC         | 3.1 +/- 1.2    | 36.7 +/- 16.9  | <0.0001 |
| Neutrophils | 0.9 +/- 0.4    | 17.5 +/- 9.8   | 0.0002  |
| Monocytes   | 0.3 +/- 0.2    | 3.3 +/- 2.3    | 0.0005  |
| Platelets   | 202.3 +/- 86.1 | 151.6 +/- 11.2 | 0.46    |

# BMAC equipment and draw technique matters more than other Orthobiologics



Second Annual

## Regenerative Orthopedic Patient Outcomes Report

2022

### Bone Marrow Aspiration Concentrate

#### The Research

In clinical studies, bone marrow aspiration concentrate (BMAC) injections have been evaluated as an alternative to knee, hip or spine surgery.<sup>27</sup> Bone marrow cells and platelets along with cytokines and growth factors in the bone marrow, may help in tissue healing.<sup>14</sup> In addition, BMAC has been shown to decrease inflammation, assist with wound healing and repair non healing bone or cartilage injuries.<sup>11,12,14</sup> Although BMAC has shown promising results, much like PRP, more research will be necessary to fully understand the benefits of this emerging treatment.



Strong Evidence

Supports the use of bone marrow injection for **knee osteoarthritis** and **low back pain**.<sup>11,28</sup>




Emerging Evidence


For **degenerative meniscal tear**, or **hip capsular injury**, **intervertebral disc repair** and **patellar tendinopathy**.<sup>29,30,31</sup>

#### BMAC processing methods

#### Our Outcomes Data



of patients experienced a meaningful reduction in pain at 12-months following treatment



Average patient reported pain (0-10) following BMAC treatment across all conditions



To centrifuge or not to centrifuge?

# Numbers of MSC's in Bone Marrow Aspirate

|                                   | Bone Marrow Aspirate |
|-----------------------------------|----------------------|
| TNC's or WBC                      | 10-25 Million TNC/cc |
| MSCs                              | 0.025--.01% of TNC's |
| HSC's, platelets, plasma proteins | YES                  |

Using The Midpoint of the Range

$17,500,000/\text{cc (TNC)} \times 0.00625\% = 1094 \text{ MSC/cc of BMA}$


**ONLY IF DRAW TECHNIQUE IS METICULOUS**

Concentrating systems for BMA can further concentrate the MSC/cc from 3-6 times over BMA

$\Rightarrow 4.5\text{x concentration} \times 1094 = 4923 \text{ MSC/CC of BMC}$

# BMAC 2.0 Regenerative Medicine Specific Needles

&  
BMC (Centrifugation) vs Bone Marrow Aspirate



## A Comparative Quantification in Cellularity of Bone Marrow Aspirated with two New Harvesting Devices, and The Non-equivalent Difference Between A Centrifugated Bone Marrow Concentrate And A Bone Marrow Aspirate As Biological Injectates, Using A Bi-Lateral Patient Model

Peter A. Everts<sup>1\*</sup>, John Ferrell<sup>2</sup>, Christine Brown Mahoney<sup>3</sup>, Glenn Flanagan II<sup>4</sup>, Moises Irizarry-de Roman<sup>5</sup>, Rowan Paul<sup>6</sup>, Natalie Stephens<sup>7</sup>, Kenneth Mautner<sup>8</sup>

- ▶ AS-BMA >MC-BMA
  - ▶ AS-BMA had higher CFU/f and TNC concentrations
  - ▶ AS-BMA 1,060/ml,  $33.5 \times 10^6$ /ml vs MC-BMA 610/ml and  $28.6 \times 10^6$ /ml
  - ▶ Comparable Platelet and RBC concentration
- ▶ After centrifugation
  - ▶ AS-BMC>MC-BMA with regard to
    - ▶ CFU/f, CD34+ cells, TNCs, platelets, and RBCs
    - ▶ Significantly higher cell yields, fewer RBC's, lower hematocrit




**Figure 5:** Change in CD34 + cells, CFU/f, and TNC concentrations after centrifugation of bone marrow aspirate collected with the AS-BMAD to produce a bone marrow concentrate. Abbreviation: BMA: Bone marrow aspirate; BMC: bone marrow concentrate; CFU/f: colony forming units for fibroblasts; TNC: total nucleated cells.

CFU/f increased from 316-  
1157 (3.66x)




**Figure 4:** Change in hematocrit, RBC, and platelet concentrations after centrifugation of bone marrow aspirate collected with the AS-BMAD to produce a bone marrow concentrate. Abbreviation: BMA: Bone marrow aspirate; BMC: bone marrow concentrate; HCT: hematocrit; RBC: red blood cell; PLT: platelet

By centrifuging, you get about 5x over baseline PRP!

# Benefits of centrifugation


- ▶ At least 3-6 x MSC's/Cfu-f
- ▶ Potentially 5-6x over baseline PRP
- ▶ Decreased RBCs
  - ▶ RBC's trigger chondrocyte apoptosis, long term inhibition of proteoglycan synthesis and damage to cartilage
  - ▶ Free hemoglobin stimulates expression of ADAMTS-5 and 9 by synovial cells possibly causing cartilage damage.
  - ▶ RBC's cause flares in injected areas.
- ▶ Concentration into a smaller volumes for smaller target structures

# Where is the best place to Aspirate Bone Marrow?


- ▶ PSIS Iliac crest- Safest, highest numbers and in vitro potential
- ▶ ASIS: acceptable but more risk than PSIS
- ▶ PSIS has more than 2x MSC's/TNC's vs Tibia or Calcaneus
- ▶ MSC's from PSIS
  - ▶ Desirable immunophenotype AND in vitro potential
  - ▶ Better differentiation into osteoblasts, chondroblasts

Understanding Bone safety zones during bone marrow aspiration from the iliac crest: the sector rule. Hernigou J, et al. International Orthopaedics. 2014  
Bone Marrow Mesenchymal stem cell aspirates from alternative sources: is the knee as good as the iliac crest? Narbone-Carceles J, Injury. 2014

# Hernigou Intl Orthopaedics 2014



# Does Age Matter? Age and CFU=F



Centeno, C 9/2019  
.Cryopreserved BMC for  
posthoc CFU analysis


## Bone Marrow Aspiration Technique Matters to maximize dose

- ▶ 1-4 ml hard pulls with multiple 10 ml syringes
- ▶ Minimizes peripheral blood contamination
- ▶ 300% Higher concentrations of MSC with 10ml syringe vs 50 in matched controls ( $p < 0.01$ )

Comparative Study > Int Orthop. 2013 Nov;37(11):2279-87. doi: 10.1007/s00264-013-2017-z.  
Epub 2013 Jul 24.


### **Benefits of small volume and small syringe for bone marrow aspirations of mesenchymal stem cells**

Philippe Hernigou <sup>1</sup>, Yasuhiro Homma, Charles Henri Flouzat Lachaniette, Alexandre Poignard, Jerome Allain, Nathalie Chevallier, Helene Rouard



# Technique matters

- ▶ Smooth penetration and fast smooth pulls
- ▶ Regenerative medicine specific centrifuges, hand processing and needles



Rowan Paul, M.D.


Review > Regen Ther. 2019 May 10;11:56-64. doi: 10.1016/j.reth.2019.03.009.

eCollection 2019 Dec.

## Assessing clinical implications and perspectives of the pathophysiological effects of erythrocytes and plasma free hemoglobin in autologous biologics for use in musculoskeletal regenerative medicine therapies. A review

Peter A Everts<sup>1</sup>, Gerard A Malanga<sup>2 3</sup>, Rowan V Paul<sup>4 5 6</sup>, Joshua B Rothenberg<sup>7 8</sup>, Natalie Stephens<sup>9</sup>, Kenneth R Mautner<sup>10 11</sup>

# Guidance Matters



# Guidance Matters



<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6349666/>

# SAVE THE DATE FOR BIOLOGICS AT THE BEACH

13TH ANNUAL



ORTHOBIOLOGICS SYMPOSIUM

## DIPLOMAT HOTEL

HOLLYWOOD | FLORIDA



JUNE 9-11, 2022

SYMPOSIUM | WORKSHOPS | CADAVER LAB

[www.tobicongress.com](http://www.tobicongress.com)



**AMERICAN SOCIETY OF  
INTERVENTIONAL PAIN PHYSICIANS**  
THE VOICE OF INTERVENTIONAL PAIN MANAGEMENT



Questions?

# Thank You!



Rowan Paul, M.D.

## RegenCore

# References:

- 1) Conley CL. Hemostasis. In: Mountcastle VB, editor. Medical Physiology. St. Louis: The C.V. Mosby Company; 2004. pp. 1137–46.
- 2) Harrison P, Cramer EM. Platelet alpha-granules. Blood Rev. 1993;7:52–62.
- 3) Schliephake H. Bone growth factors in maxillofacial skeletal reconstruction. Int J Oral Maxillofac Surg. 2002;31:469–84.
- 4) Tobita M, et al. Adipose tissue-derived mesenchymal stem cells and platelet-rich plasma: stem cell transplantation methods that enhance stemness. Stem Cell Res Ther. 2015; 6: 215. [
- 5) [Ahmad T<sup>1</sup>](#), et al. Miro1 regulates intercellular mitochondrial transport & enhances mesenchymal stem cell rescue efficacy. [EMBO J](#). 2014 May 2;33(9):994-1010. doi: 10.1002/embj.201386030. Epub 2014 Jan 15.
- 6) [Biancone L<sup>1</sup>](#), et al. **Therapeutic potential of mesenchymal stem cell-derived microvesicles.** [Nephrol Dial Transplant](#). 2012 Aug;27(8):3037-42. doi: 10.1093/ndt/gfs168.
- 7) [Muschler GF<sup>1</sup>](#), et al. **Aspiration to obtain osteoblast progenitor cells from human bone marrow: the influence of aspiration volume.** [J Bone Joint Surg Am](#). 1997 Nov;79(11):1699-709.
- 8) Nicole M. Gordon, MS, et al . **Biologically Enhanced Healing of the Rotator Cuff.** [Orthopedics](#). [June 2012 - Volume 35 - Issue 6: 498-504](#)
- 9) [Bruce Werber](#). **Amniotic Tissues for the Treatment of Chronic Plantar Fasciosis and Achilles Tendinosis.** [J Sports Med \(Hindawi Publ Corp\)](#). 2015; 2015: 219896. Published online 2015 Sep 27. doi: [10.1155/2015/219896](#)
- 10) E. Rodriguez-Collazo, [Open surgical implantation of a viable cryopreserved placental membrane after decompression and neurolysis of common peroneal nerve: a case series](#). [J Orthop Surg Res](#). 2017; 12: 88. Published online 2017 Jun 12. doi: 10.1186/s13018-017-0587-y
- 11) [Lane, Sanderson](#). **Effectiveness and safety of prolotherapy injections for management of lower limb tendinopathy and fasciopathy: a systematic review.** [J Foot Ankle Res](#). 2015; 8: 57. Published online 2015 Oct 20. doi: [10.1186/s13047-015-0114-5](#)
- 12) [Ross A. Hauser](#), **A Systematic Review of Dextrose Prolotherapy for Chronic Musculoskeletal Pain** [Clin Med Insights Arthritis Musculoskelet Disord](#). 2016; 9: 139–159.
- 13) [David Rabago](#), **Dextrose Prolotherapy for Knee Osteoarthritis: A Randomized Controlled Trial.** [Ann Fam Med](#), 11 (3), 229-237. May 2013
- 14) [Linda V. Thomas](#), et al. **Exploring the influence of the gut microbiota and probiotics on health: a symposium report.** [Br J Nutr](#). 2014 Jul; 112(Suppl 1): S1–S18. doi: [10.1017/S0007114514001275](#)
- 15) Dragoo et al. Poster No. 1329 • ORS 2012 Annual Meeting. Rabbit Tendon Model
- 16) [Am J Sports Med](#). 2016 Mar;44(3):792-800. doi: 10.1177/0363546515580787. Epub 2015 Apr 29. **Effect of Leukocyte Concentration on the Efficacy of Platelet-Rich Plasma in the Treatment of Knee Osteoarthritis.** [Riboh JC<sup>1</sup>](#), [Saltzman BM<sup>2</sup>](#), [Yanke AB<sup>2</sup>](#), [Fortier L<sup>3</sup>](#), [Cole BJ<sup>2</sup>](#).
- 17) [Valerie A. Siclari](#), et al. **Mesenchymal Progenitors Residing Close to the Bone Surface Are Functionally Distinct from Those in the Central Bone Marrow.** [Bone](#). 2013 Apr; 53(2): 575–586.